etidronate has been researched along with Osteonecrosis in 28 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw." | 3.76 | Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010) |
| "They are indicated for the treatment of osteoporosis." | 2.44 | Osteochemonecrosis of jaws and bisphosphonates. ( Beirne, JC; Khosa, AD; Nayyar, MS, 2007) |
| "etidronate) have been associated with acute renal failure." | 2.44 | Safety considerations with bisphosphonates for the treatment of osteoporosis. ( Civitelli, R; Emkey, R; Strampel, W, 2007) |
| " The variety of bisphosphonates currently available to us provides a wide range of tolerability and dosing profiles thus necessitating a thorough comparison of the most recent oral and intravenous bisphosphonates to differentiate the clinical context in which they should be used." | 2.43 | Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. ( Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B, 2006) |
| "The amount of bone loss in algodystrophy in a few weeks or months is what might be expected over 10 years during the natural history of uncomplicated osteoporosis." | 2.40 | Further vascular, bone and autonomic investigations in algodystrophy. ( Audran, M; Baslé, MF; Bregeon, C; Legrand, E; Masson, C; Namour, A; Pascaretti, C; Renier, JC; Saumet, JL, 1998) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| "The present study was designed to evaluate the effects of risedronate, one of the most potent bisphosphonates, on alveolar bone resorption and angiogenesis in rats with experimental periodontitis to identify dose-response curves and treatment durations that can be therapeutic for periodontal therapy versus those associated with osteonecrosis of the jaws." | 1.35 | Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats. ( Ayas, B; Cetinkaya, BO; Gurgor, P; Keles, GC, 2008) |
| "Most reports of osteonecrosis are attributed to the use of bisphosphonates administered intravenously for the treatment of bone disorders such as multiple myeloma." | 1.35 | Osteonecrosis associated with short-term oral administration of bisphosphonate. ( Harada, A; Sumi, Y; Takagi, Y, 2009) |
| "No osteonecrosis was noted immediately postoperatively or during the follow-up period in 61 patients." | 1.34 | Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. ( Fugazzotto, PA; Jaffin, R; Kumar, A; Lightfoot, WS, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 20 (71.43) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cetinkaya, BO | 1 |
| Keles, GC | 1 |
| Ayas, B | 1 |
| Gurgor, P | 1 |
| Bennani, A | 1 |
| Rerhrhaye, W | 1 |
| Soualhi, H | 1 |
| El Wady, W | 1 |
| Geusens, P | 1 |
| Takagi, Y | 1 |
| Sumi, Y | 1 |
| Harada, A | 1 |
| Kunchur, R | 1 |
| Need, A | 1 |
| Hughes, T | 1 |
| Goss, A | 1 |
| Lo, JC | 1 |
| O'Ryan, FS | 1 |
| Gordon, NP | 1 |
| Yang, J | 1 |
| Hui, RL | 1 |
| Martin, D | 1 |
| Hutchinson, M | 1 |
| Lathon, PV | 1 |
| Sanchez, G | 1 |
| Silver, P | 1 |
| Chandra, M | 1 |
| McCloskey, CA | 1 |
| Staffa, JA | 1 |
| Willy, M | 1 |
| Selby, JV | 1 |
| Go, AS | 1 |
| Kwon, YD | 1 |
| Kim, DY | 1 |
| Ohe, JY | 1 |
| Yoo, JY | 1 |
| Walter, C | 1 |
| Yamaguchi, K | 2 |
| Oizumi, T | 2 |
| Funayama, H | 2 |
| Kawamura, H | 2 |
| Sugawara, S | 2 |
| Endo, Y | 2 |
| Gates, BJ | 1 |
| Sonnett, TE | 1 |
| Duvall, CA | 1 |
| Dobbins, EK | 1 |
| Yokoyama, M | 1 |
| Takahashi, H | 1 |
| Yamamoto, M | 1 |
| Kuroishi, T | 1 |
| Kumamoto, H | 1 |
| Sasaki, K | 1 |
| Migliorati, CA | 1 |
| Mattos, K | 1 |
| Palazzolo, MJ | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Pazianas, M | 1 |
| Scully, C | 1 |
| Bornstein, MM | 1 |
| Oberli, K | 1 |
| Stauffer, E | 1 |
| Buser, D | 1 |
| Bobba, RS | 1 |
| Beattie, K | 1 |
| Parkinson, B | 1 |
| Kumbhare, D | 1 |
| Adachi, JD | 1 |
| Brooks, JK | 1 |
| Gilson, AJ | 1 |
| Sindler, AJ | 1 |
| Ashman, SG | 1 |
| Schwartz, KG | 1 |
| Nikitakis, NG | 1 |
| Khosa, AD | 1 |
| Nayyar, MS | 1 |
| Beirne, JC | 1 |
| Malden, NJ | 1 |
| Pai, AY | 1 |
| Strampel, W | 1 |
| Emkey, R | 1 |
| Civitelli, R | 1 |
| Fugazzotto, PA | 1 |
| Lightfoot, WS | 1 |
| Jaffin, R | 1 |
| Kumar, A | 1 |
| Marx, RE | 1 |
| Cillo, JE | 1 |
| Ulloa, JJ | 1 |
| Khan, A | 1 |
| Udvardy, E | 1 |
| Redl, P | 1 |
| Márton, I | 1 |
| Burt, RW | 1 |
| Matthews, TJ | 1 |
| Masson, C | 1 |
| Audran, M | 1 |
| Pascaretti, C | 1 |
| Namour, A | 1 |
| Saumet, JL | 1 |
| Baslé, MF | 1 |
| Legrand, E | 1 |
| Bregeon, C | 1 |
| Renier, JC | 1 |
9 reviews available for etidronate and Osteonecrosis
| Article | Year |
|---|---|
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Frac | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceut | 2009 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone | 2011 |
[Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature].
Topics: Administration, Oral; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Ac | 2006 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporo | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphospho | 2007 |
[Osteonecrosis of the jaw developing during bisphosphonate treatment].
Topics: Alendronate; Anti-Infective Agents; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodelin | 2008 |
Further vascular, bone and autonomic investigations in algodystrophy.
Topics: Absorptiometry, Photon; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Vessels; | 1998 |
1 trial available for etidronate and Osteonecrosis
| Article | Year |
|---|---|
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Co | 2009 |
18 other studies available for etidronate and Osteonecrosis
| Article | Year |
|---|---|
Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats.
Topics: Alveolar Bone Loss; Alveolar Process; Animals; Blood Vessels; Bone Density; Bone Density Conservatio | 2008 |
[Non traumatic tooth extraction in patients treated by bisphosphonate].
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Mandibular Diseases; Orthodo | 2008 |
Osteonecrosis associated with short-term oral administration of bisphosphonate.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Denture, Partial, Removable; Etidronic | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Section | 2010 |
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Ag | 2009 |
Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Bone Density Conservation Agents; Diphosphonates; Eti | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conser | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female | 2005 |
Potential adverse effects.
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw Diseases; Osteonecrosis; Periodontal D | 2006 |
Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Dental Implantation, Endosseous; Etidr | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidron | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo | 2007 |
Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental | 2007 |
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidroni | 2007 |
Osteonecrosis of the jaw: new developments in an old disease.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Eti | 2008 |
Aseptic necrosis of the knee: bone scintigraphy.
Topics: Adolescent; Adult; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Kidney Transplantation; Kn | 1982 |